-
1.发明公开公开(公告)号：US20240050485A1
公开(公告)日：2024-02-15
申请号：US18449657
申请日：2023-08-14
发明人： Thomas E. ICHIM , Timothy G. DIXON , Feng LIN , James VELTMEYER
IPC分类号： A61K35/28 , C12N5/0775 , A61P11/00
CPC分类号： A61K35/28 , C12N5/0663 , A61P11/00
摘要： Disclosed are means, treatments and compositions of matter useful for treatment of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse reduction in lung function associated with COPD. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of pulmonary regeneration directly or indirectly.
-
公开(公告)号：US20220362341A1
公开(公告)日：2022-11-17
申请号：US17744590
申请日：2022-05-13
IPC分类号： A61K38/20 , A61P25/24 , A61K31/09 , A61K33/241 , A61K31/164 , A61K31/375 , A61K31/4748 , A61K31/4365 , A61K31/352 , A61K31/05 , A61K31/121 , A61K31/047 , C12N15/113
摘要： Disclosed are methods, compositions of matter, and protocols useful for treatment of major depressive disorder through administration of low dose interleukin-2 at a concentration and/or frequency sufficient to increase expansion of T regulatory cell numbers and/or enhancement of T regulatory cell activity. In some embodiments administration of interleukin-2 is provided as means of enhancing efficacy of standard antidepressant therapies. Furthermore, administration of interleukin-2 receptor agonists is also described in the current invention as a treatment of major depressive disorder.
-
公开(公告)号：US20220031793A1
公开(公告)日：2022-02-03
申请号：US17387158
申请日：2021-07-28
IPC分类号： A61K36/82 , A61K31/09 , A61K36/45 , A61K36/71 , A61K36/31 , A61K31/353 , A61K31/122 , A61K31/26
摘要： Disclosed are means, compositions of matter, and protocols useful for neuroprotection and neuroregeneration. In one embodiment the invention provides administration of pterostilbene alone or in combination with other ingredients to induce neuroprotection and/or neuroregeneration. The invention teaches protection/regeneration in conditions associated with neurological inflammation and/or other congenital or acquired neurodegenerative diseases.
-
4.发明公开公开(公告)号：US20240241119A1
公开(公告)日：2024-07-18
申请号：US18410531
申请日：2024-01-11
IPC分类号： G01N33/569
CPC分类号： G01N33/56972 , G01N2333/5428 , G01N2333/70596
摘要： Disclosed are novel means of stratifying patients into potential of positive response to mesenchymal stem cell therapy based on quantification of pretreatment levels of B regulatory cells. In one embodiment quantification of cells concurrently expressing CD5 and CD19. In another embodiment B regulatory cells are CD19+CD39−IL10+. In one embodiment the selection of B regulatory cells is quantified by flow cytometric means and patients possessing more than 7% IL-10 secreting CD19 cells are chosen for stem cell therapy. In some embodiments numbers of B regulatory cells are increased prior to treatment by administration of various interventions including providing GM-CSF, microbiome alteration or manipulation of oxidative stress.
-
5.发明公开公开(公告)号：US20240156862A1
公开(公告)日：2024-05-16
申请号：US18508623
申请日：2023-11-14
CPC分类号： A61K35/15 , A61P11/00 , C07K16/244 , C12N5/0634 , C12N2501/22 , C12N2501/2303
摘要： Disclosed are compositions of matter, protocols, and treatment means for prevention and/or reversing Chronic Obstructive Pulmonary Disease (COPD) using myeloid derived suppressor cells as a monotherapy or adjuvant therapy. In one embodiment umbilical cord low density myeloid cells are expanded using interleukin-3 and GM-CSF and administered in an allogeneic manner to a mammal suffering from COPD. In some embodiments combinations of myeloid derived suppressor cells and mesenchymal stem cells are disclosed.
-
6.发明公开公开(公告)号：US20240034996A1
公开(公告)日：2024-02-01
申请号：US18361712
申请日：2023-07-28
IPC分类号： C12N5/0784 , C12N5/0775
CPC分类号： C12N5/0639 , C12N5/0662 , C12N2506/45 , C12N2501/60 , C12N2501/603 , C12N2501/602 , C12N2501/605 , C12N2501/73
摘要： Disclosed are cells and cellular compositions useful for treatment of degenerative and/or autoimmune diseases derived from gene edited/gene modified pluripotent stem cells. In one embodiment pluripotent stem cell such as inducible pluripotent stem cells are gene modified to express tissue associated transcription factors such as pdx-1 if endodermal tissue is desired and cells are differentiated into regenerative-type cells such as along the mesenchymal lineage. In one embodiment the invention teaches transfection with IL-27 to induce expression of coinhibitory molecules for suppression of autoimmunity. In some embodiments the invention provides generation of iPSC derived MSC which can not stimulate inflammation due to gene-editing based removal of inflammatory associated transcription factors.
-
公开(公告)号：US20230047535A1
公开(公告)日：2023-02-16
申请号：US17886407
申请日：2022-08-11
IPC分类号： A61K35/51 , C12N5/0775 , A61P25/00 , C12N5/077
摘要： Disclosed are means, compositions of matter and protocols useful for treatment of neurological dysfunctions through stimulation of adult neurogenesis using administration of umbilical cord derived mesenchymal stem cells such as JadiCells. In one embodiment viral induced neuropathy is reduced by administration of JadiCells to stimulate neurogenesis. In another embodiment the neurogenic activity of selective serotonin reuptake inhibitors is enhanced by administration of JadiCells. In some embodiments administration of JadiCell exosomes, conditioned media, microvesicles and/or apoptotic bodies is utilized to stimulate neurogenesis.
-
公开(公告)号：US20240216472A1
公开(公告)日：2024-07-04
申请号：US18404724
申请日：2024-01-04
CPC分类号： A61K38/2066 , A61K9/0019 , A61K38/1709 , A61K45/06 , A61P37/06
摘要： Disclosed are means, methods, and compositions of matter useful for induction of antigen specific suppression of immunity and/or tolerogenesis through administration of tolerogenic agents together with antigens and/or modified antigens delivered via multiple intradermal injections. In one embodiment the invention teaches the use of a tattoo gun or a similar device to administer over an extended area of skin a compound which induces a tolerogenic microenvironment and subsequently administration of said antigen in the artificially created microenvironment. The essence of the disclosed invention is the superior tolerogenic effects observed when tolerogenic stimuli and antigen are administered over an extended area of skin through the use of a tattoo gun or similar device
-
公开(公告)号：US20240082356A1
公开(公告)日：2024-03-14
申请号：US18465972
申请日：2023-09-12
CPC分类号： A61K38/193 , A61K31/09 , A61K35/28 , A61P11/00
摘要： Disclosed are means of inducing pulmonary regeneration and/or protection from oxidative stress by stimulation of endogenous stem cell mobilization together with one or more inhibitors of NF-kappa B and/or one or more inhibitors of oxidative stress. The invention discloses the unexpected finding that G-CSF administration enhances oxidative stress and pulmonary damage, however, coadministration with pterostilbene, results in synergistic suppression of COPD pathology.
-
公开(公告)号：US20230301938A1
公开(公告)日：2023-09-28
申请号：US18106925
申请日：2023-02-07
发明人： Thomas ICHIM , Timothy G. DIXON
IPC分类号： A61K31/09 , A61K31/122 , A61K31/26 , A61K36/71 , A61K36/82
CPC分类号： A61K31/09 , A61K31/122 , A61K31/26 , A61K36/71 , A61K36/82
摘要： Disclosed are means and methods of treating cognitive dysfunction associated with COVID-19 and/or other associated with inflammatory conditions. In one embodiment treatment of COVID-19 cognitive dysfunction performed by administration of nutraceutical means, wherein said nutraceuticals are administered at a frequency and/or concentration sufficient to induce proliferation of endogenous neural progenitor cells and/or protect cells from inflammatory damage. In one embodiment said nutraceuticals are comprised of green tea extract, and/or nigella sativa, and/or pterostilbene, and/or sulforaphane. In some embodiments nutraceutical compositions are utilized to overcome treatment resistant of currently used antidepressants.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.016 秒)
